Novavax (NVAX) Appoints Charles Newton to its Board

Novavax, Inc. (Nasdaq: NVAX) today announced the appointment of Charles Newton to its board as an independent director. Mr. Newton brings extensive experience in public markets and healthcare investment banking to his role on the Novavax Board of Directors.

"Charles brings a wealth of expertise across corporate finance and capital markets to Novavax," said John C. Jacobs, President and Chief Executive Officer, Novavax. "The knowledge he brings to our already experienced board will be invaluable as we continue to execute our corporate growth strategy focused on forging strategic partnerships for our R&D assets and our Matrix-M® adjuvant."

Mr. Newton currently serves as Chief Financial Officer of Lyell Immunopharma, with past leadership experience in healthcare investment banking at Bank of America Merrill Lynch, Credit Suisse and Morgan Stanley.

"This is a very exciting time to be joining the Novavax Board," said Mr. Newton. "I am looking forward to supporting the innovative partnership work the Company is prioritizing to ensure broad access to its cutting-edge technology platform, including its proprietary Matrix-M® adjuvant, while bringing maximum value to shareholders."

Mr. Newton brings vast board experience to Novavax as well. He currently serves as a member of the board of directors of Coherus BioSciences and 2seventy bio, Inc. Mr. Newton holds a Bachelor of Science degree in Finance from Miami University and a Master of Business Administration from The Tuck School at Dartmouth College.

You May Also Be Interested In

• Longeveron names Nirav Jhaveri as CFO
• Morgan Stanley Upgrades Merck (MRK) to Overweight
• Neutron Holdings (LIME) Reiterated at Market Outperform by Citizens on Raised Ride Prices